JB Chemicals and Pharmaceuticals, which sold its over-the-counter brands in Russia, plans to focus on its contract research and manufacturing business to build its position in the sector, reports Reuters.
Par Pharmaceutical Cos. would acquire India-based generic drug maker Edict Pharmaceuticals for up to $37.6 million. The company expects the deal to close by the end of the year and add to earnings in 2013, reports The Wall Street Journal.
ChrysCapital chief Ashish Dhawan-backed pharma company JB Chemicals & Pharmaceuticals has sold its Russia/CIS over-the-counter products business to Cilag GmbH International, an arm of the global healthcare giant Johnson & Johnson, for $260 million (Rs 1,170 crore) in cash. The sale includes cough syrup brands Doktor Mom and Rinza, reports vccircle.com.
Tobacco addiction among adolescents is a major challenge in the fight against smoking even as Hyderabad braces itself to slew of awareness drives during the upcoming ‘World No Tobacco Day' on May 31.
Hyderabad-based drug-maker Aurobindo Pharma received a warning letter from the US health regulator with regard to its antibiotics manufacturing unit in Andhra Pradesh.
Cancer patients and their family members, who die a “double death” when they see the medical bills, may have something to cheer about in Andhra Pradesh. According to a report in Deccan Chronicle, the Visakhapatnam district collectorate and the Drug Control Administration (DCA) initiated Asha Jyothi, a pilot project to offer drugs at discounts ranging from 20 to 85 per cent to cancer patients.
India has joined a global network of scientific research on measures to be better protected against animal diseases like avian flu and foot and mouth that adversely hit the economy of several countries and affect millions of people directly or indirectly, reports PTI from London.
Global pharma major Sanofi has entered into a license agreement with Glenmark Pharmaceuticals SA, a wholly owned unit of India’s Glenmark Pharma for development and commercialization of GBR500, a monoclonal antibody to treat Crohn’s disease and other chronic autoimmune disorders.
GVK Biosciences (GVK BIO) on Monday announced that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK BIO is the only partner that is headquartered in India.
It may sound strange but it is true. Killing a mouse or even injuring it in a lab will attract a jail term up to five years with fine, reports The Times of India
Russia’s Yaroslavl Region has been seeking expertise from the Indian pharmaceutical companies to build a world class pharma cluster in the region. The Region has inked agreements with leading pharma companies to bring about a phased transition to manufacturing in Russia, according to Russia and India Report
Madhya Pradesh led by Indore is poised to play a major role in the Indian pharmaceutical market, which is expected to rise from the present size of Rs.1,00,000 crore ($21 billion) to Rs.2,25,000 crore ($50 billion) by 2020, reports Pharmabiz.
Aurobindo Pharma Ltd's consolidated net profit remained flat at Rs 563.45 crore for 2010-11, compared with Rs 563.40 crore a year ago. This is despite a 22.7 per cent increase in sales income to Rs 4,480.98 crore from Rs 3,651.33 crore.
Small and medium-sized pharmaceutical companies are rattled with the Director General of Foreign Trade order on bar coding as they fear it would increase input costs and adversely impact exports from the country.
Amid hot competition among the top four firms in the Indian pharmaceutical market, Ranbaxy Laboratories has emerged as the fastest growing company in the first quarter of 2011.
